Resistance to current therapeutic interventions is a major challenge in the treatment of patients affected by cancer. While nitricoxide (NO) might have proneoplastic properties, it is now clear that at high doses, NO has a role in cancertherapeutics. Either as a single agent or in combination with other antineoplastic compounds, NO might be used to overcome tumor cell resistance to conventional treatments. The following discussion addresses the role of NO in cancertherapeutics and includes a report on the role of NO donors in the area of cancertherapeutics.
Click here to view the full article in Future Science Open Access.